Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility Medical Dialogues Bureau1 April 2020 7:14 AM GMTBengaluru: Biocon Sdn Bhd, a subsidiary of Biocon Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S. FD...
Biocon, Mylan win patent rights for Insulin Glargine Device against Sanofi Medical Dialogues Bureau12 March 2020 5:59 AM GMTInsulin Glargine is a long-acting insulin used to treat adults with Type 2 diabetes and adults and paediatric patients with Type 1 diabetes for the...
USFDA Accepts Biocon, Mylan's application for review of Proposed Biosimilar of Bevacizumab Medical Dialogues Bureau10 March 2020 7:45 AM GMTBiocon Ltd. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...
Biocon Small Molecules API Manufacturing Facility Completes Post -Approval and GMP USFDA Inspection Medical Dialogues Bureau29 Feb 2020 6:05 AM GMTNew Delhi: Drug API maker, Biocon has informed that the U.S. Food and Drug Administration (FDA) conducted a Post-Approval and GMP inspection of Small...
